NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.40% | 19.21% | -18.60% | -1.33% | 14.82% |
| Total Depreciation and Amortization | 34.25% | 33.09% | 27.00% | 10.45% | 6.01% |
| Total Amortization of Deferred Charges | 0.19% | 0.19% | 12.06% | 12.06% | 12.06% |
| Total Other Non-Cash Items | 4.00% | -32.02% | 49.62% | 50.96% | 40.94% |
| Change in Net Operating Assets | 90.22% | -450.15% | -101.34% | -420.91% | -237.91% |
| Cash from Operations | 11.74% | -85.94% | 8.00% | 33.48% | 65.46% |
| Capital Expenditure | 49.17% | 37.82% | 24.65% | 4.24% | -27.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 234.57% | 576.37% | 416.12% | 114.26% | -192.22% |
| Cash from Investing | 214.90% | 411.80% | 503.15% | 240.35% | -212.89% |
| Total Debt Issued | 3.15% | 3.15% | 3.15% | -100.00% | -- |
| Total Debt Repaid | -4,244.03% | -4,244.03% | 100.00% | 100.00% | -430,333.33% |
| Issuance of Common Stock | -56.68% | 54.92% | 96.29% | 57.82% | 5.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -579.04% | -599.74% | 23.78% | -88.50% | 783.19% |
| Foreign Exchange rate Adjustments | -66.06% | 326.44% | 122.08% | 1,603.33% | 220.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.21% | 18.00% | 375.54% | -248.96% | -221.13% |